Bluejay Diagnostics Announces Closing of $3.5 Million
From GlobeNewswire:
Bluejay Diagnostics, Inc. closed a public offering of 2,692,308 shares of common stock and warrants to purchase up to 2,692,308 shares, raising approximately $3.5 million. H.C. Wainwright & Co. acted as the exclusive placement agent. The net proceeds will be used for FDA approval and other research and development activities. The offering was made via a registration statement on Form S-1 and is only available by prospectus. Bluejay focuses on improving patient outcomes with its Symphony System, providing a rapid, near-patient testing system for sepsis and monitoring disease progression. This press release contains forward-looking statements. For further information, visit www.bluejaydx.com.
Read more: Bluejay Diagnostics Announces Closing of $3.5 Million